CN1068226C - Venereal disease preventing medicine containing interferon - Google Patents
Venereal disease preventing medicine containing interferon Download PDFInfo
- Publication number
- CN1068226C CN1068226C CN 97109122 CN97109122A CN1068226C CN 1068226 C CN1068226 C CN 1068226C CN 97109122 CN97109122 CN 97109122 CN 97109122 A CN97109122 A CN 97109122A CN 1068226 C CN1068226 C CN 1068226C
- Authority
- CN
- China
- Prior art keywords
- interferon
- medicine
- std
- povidone iodine
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000014150 Interferons Human genes 0.000 title claims abstract description 27
- 108010050904 Interferons Proteins 0.000 title claims abstract description 27
- 229940079322 interferon Drugs 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title claims abstract description 24
- 230000003405 preventing effect Effects 0.000 title claims abstract description 13
- 201000010099 disease Diseases 0.000 title abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 8
- 239000002502 liposome Substances 0.000 claims abstract description 14
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims description 20
- 229920000153 Povidone-iodine Polymers 0.000 claims description 20
- 229960001621 povidone-iodine Drugs 0.000 claims description 20
- 208000015891 sexual disease Diseases 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000000829 suppository Substances 0.000 abstract description 10
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 abstract 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 abstract 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 39
- 230000002265 prevention Effects 0.000 description 8
- 210000001215 vagina Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 206010059313 Anogenital warts Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010018612 Gonorrhoea Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000001786 gonorrhea Diseases 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940127249 oral antibiotic Drugs 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 239000000934 spermatocidal agent Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- -1 iodole ketone Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000003507 refrigerant Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229940035535 iodophors Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000000260 male genitalia Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to an interferon-contained medicine for preventing venereal diseases, which comprises iodophor. The medicine is characterized in that the medicine comprises interferon liposomes in nature. The interferon-contained medicine for preventing venereal diseases keeps the preventing effects of the iodophor, and meanwhile, cauliflower excrescence can be effectively prevented; the medicine can be prepared into suppositories, so the use is convenient.
Description
The invention belongs to medicine for preventing sexual disease.
From world wide, the infection rate and the sickness rate of sexually transmitted disease (STD) rise year by year, and popular scope constantly enlarges, and the extent of injury is on the rise, and the spread of aids that is called as " 20 century plague " is rapid, causes global shock.At present, in some Hesperian diseases constituted, sexually transmitted disease (STD) was occupied critical role, and its sickness rate almost accounts for the over half of various infectious disease sums.The popular advantage of sexually transmitted disease (STD) is sick plants to gonorrhea, accounts for 60% of whole sexually transmitted disease (STD)s.Secondly be condyloma acuminatum, nongonococcal urethritis.There are 200,000,000 gonorrhea new patients in the whole world every year approximately, and wherein most patient is failed to report.2% is infected in the total population of sex life ability is arranged, with the sexual contactee 50-90% of gonorrhea patient can be infected.China's std patient pre-peaceful liberation period is many, and number of patients reached more than 1,000 ten thousand people in 1949.After liberation, Party and government attach great importance to prevention and treatment of venereal diseases work, basic disappearance sexually transmitted disease (STD) in 1964.
Sexually transmitted disease (STD) is revivable in China the eighties, nearly 30,000 people of national patient in 1986, nineteen ninety reaches 200,000 people, in particular locality, in special populations such as open city, tourist spot, drugs distribution centre, the infection rate of sexually transmitted disease (STD) and sickness rate have reached higher level.Secondly the morbidity of mahjong city is the minority area at most on the south China's sexually transmitted disease (STD), and the case in each province and city, the Yangtze river basin increases the fastest.From the whole nation, the morbidity by the city to rural area, south north, coastal upcountry the diffusion spread.This spreading rapidly, involve wide, sickness rate is high, the general susceptible of crowd, this causes huge psychological impact to the resident that sexuality is arranged.
At present, considerable work has been done to prevention, treatment sexually transmitted disease (STD) by health ministry health and epidemic prevention department, but sexually transmitted disease (STD) is not still had artificial immunity both at home and abroad up to now, and the specific drug of prevention of STD is not arranged yet.How let us everyone strengthen self-special protection, the erosion of prevention of STD, this problem seems and becomes more and more important and give prominence to.
At present, both at home and abroad the method for prevention of STD mainly be 1. use condom 2. oral antibiotic 3. use spermicide.These three kinds of methods can be played a role to the prevention of sexually transmitted disease (STD), but respectively some shortcomings are arranged.Condom generally is to adopt latex material to make now, easily breaks, and when using, makes the male reduce the degree of sexual excitation, and have groups of people to use the back irritated, and a lot of male are reluctant to use.Oral antibiotic prophylaxis: bibliographical information is arranged, take antibiotics preventability disease transmission when contacting by bacterial std patient with gonorrhea, syphilis etc.Yet, indiscriminately abuses preventative antibiotic have the drug-fast danger of antibiotics takes place, and the sexually transmitted disease (STD) that oral antibiotic is caused by virus condyloma acuminatum, AIDS etc. is without any preventive effect.Use spermicide: bibliographical information is arranged, use spermicide, for venereal disease infection the preventive effect of 25-60% is arranged, but effect is not as using condom obvious.
It is the multifunctional vaginal sponge that is used to practise contraception, prevent and treat sexually transmitted disease (STD), control gynaecopathia of principal agent with the povidone iodine that Chinese patent " multifunctional vaginal sponge " 95102894.4 discloses a kind of.Povidone iodine all has very strong ability of killing and Disinfection Effect to various bacteria, mycete, virus, brood cell, infusorian etc., can effectively prevent sexually transmitted disease (STD), and life-time service does not have any toxic action.This chemical substance has been prepared into the medicine of diseases such as treatment vaginitis, cervical erosion, trichomonas vaginitis now both at home and abroad.But povidone iodine can not effectively prevent the sexually transmitted disease (STD) that accounts for this virus of deputy condyloma acuminatum in the sexually transmitted disease (STD) and cause; The sponge attitude also will be taken out sponge carrier after using from vagina on the other hand, and use has inconvenience more.
The object of the present invention is to provide a kind of medicine for preventing sexual disease that contains interferon, it has the preventive effect of both preserving povidone iodine, the advantage that can effectively prevent condyloma acuminatum again simultaneously.
Further aim of the present invention is to allow the dosage form of this medicine can make medicine continue to play a role, and needn't take out pharmaceutical carrier more again simultaneously, and is easy to use.
The sti prevention property of medicine of the present invention is characterized in that it contains povidone iodine and interferon liposome.
As above-mentioned medicine for preventing sexual disease, it is characterized in that the content of povidone iodine and interferon liposome is: povidone iodine 0.01-1g interferon liposome 0.2-3mg interferon content 0.1-100iu.As above-mentioned medicine for preventing sexual disease, it is characterized in that component content is: povidone iodine 0.08-0.8g interferon lipid 0.8-1.5mg interferon content 1-10 ten thousand iu.
Povidone iodine of the present invention and interferon liposome can have numerous selections, can use such as povidone iodine: povidon iodine, polyethoxy ethanol povidone iodine, Iodophors, iodole ketone, interferon liposome can be used: engineered α, β, γ IFN, perhaps natural α, β, γ IFN.
The interferon molecule amount is 1.8～20,000, belongs to a kind of biomacromolecule, and traditional cutaneous permeable agent dimethyl sulfoxine, azone etc. only have the transdermal facilitation to molecular weight less than 3000 micromolecule, and are powerless to this class macromole of interferon.In this medicine, interferon occurs with the plasmalogen form, can improve the Transdermal absorption of interferon greatly, makes it to give full play to drug effect.Liposome has been isolated interferon and povidone iodine simultaneously, and having solved povidone iodine influences problem to proteinic degeneration.
Embodiments of the invention are as follows:
Example formulations (by each inspection agent consumption):
α IFN liposome 1mg 20,000 iu interferon
Povidone iodine 0.1g available iodine 0.01g
Adjuvant: effect
1. microcrystalline Cellulose 0.12g disperses, dilutes
2. mannitol 0.2g dispersion, refrigerant
3. the suction of carboxymethyl starch sodium CMSNa 0.03g suppository is collapsed out
4. HPC 0.2g dispersion, dilution, carrying principal agent are adsorbed on the mucosa
5. lactic acid 0.02g transfers PH
6. ethanol 0.5ml solvent
7. Mentholum 5mg is refrigerant
8. magnesium stearate 0.02g is lubricated
9. silicone oil 0.5mg improves suppository surface slip, moisture resistance
10. hypromellose 0.4g parcel bolt outer surface strengthens slip, moisture resistance
Every on the bolt that α-I FN liposome, povidone iodine are become with adjuvant is about 1～2.5g.
Method for making:
1, with solvent evaporated method α-I FN is sealed by phospholipid and make interferon liposome, envelop rate＞75%;
2, povidone iodine with 1., 2., 3., 4. 10. mix with 1/3, make granule, 5. dry back add, 6., 7., 8. and α-IFN liposome mix homogeneously.
3, be pressed into thin flat with tablet machine, the outside strengthens the slip and the moisture resistance of suppository with 9., 10. wrapping film-coat.
This product is a broad-spectrum sterilization, antiviral drugs, be used for the vagina cleaning, sterilization and preventing-ability infecting disease condyloma acuminatum, select for use the vaginal suppository dosage form suppository to be put into the vagina deep preceding four minutes of sex partner sexual intercourse or before the longer time, suppository can discharge slowly after mucus is moistening that to provide fungicidal spectrum wide, sterilizing power is strong, and to protozoon, fungus, all effective iodine of virus and spore and interferon, suppository can all moisteningly soften into pasty state and be diffused in the vaginal wall gradually after four minutes, reach cervix uteri, the requirement of vagina sterilizing, treat to continue to prevent that male partner STD infects immersion vagina and uterine cavity after the sexual intercourse, prevent from or reduce STD significantly to infect mutually.
In addition, can also use lactose, glycerol instead in adjuvant, cmc soln is pressed emulsifiable paste manufacture method system soft paste, in the plastic flexible pipe of packing into, inserts the vagina depths during use and quantitatively clamp-ons emulsifiable paste.
The vaginal plug that the present invention makes, ointment are used for preventing that STD and other formulations relatively have following advantages:
1, local target medication, dosage is few, the curative effect height, toxic and side effect is little;
2, mucosa absorption is fast, lasting medicine, and external interference is few;
3, than barrier film, the few foreign matter of sponge kind and sense of discomfort, do not produce " distortion sense " during use;
4, volume is little, portably uses conveniently;
5, the research of relevant STD precautionary measures more and more causes various countries scholar's concern, in many methods, prevents through vaginal approach Noticeable, this approach is again take suppository as good.
In addition, the suppository that this product is made belongs to a kind of suppository of water-soluble base preparation, both can use for vagina, if after adding certain water gaging, and the very fast washing that can be dissolved into liquid for male genital organ.Thereby this medicine men and women all can use.
Claims (3)
1, a kind of medicine for preventing sexual disease that contains interferon is characterized in that it contains povidone iodine and interferon liposome.
2, medicine for preventing sexual disease as claimed in claim 1 is characterized in that the content of povidone iodine and interferon liposome is: povidone iodine 0.01-1g interferon liposome 0.2-3mg interferon content 0.1-100iu.
3, medicine for preventing sexual disease as claimed in claim 2 is characterized in that component content is: povidone iodine 0.08-0.8g interferon lipid 0.8-1.5mg interferon content 1-10 ten thousand iu.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97109122 CN1068226C (en) | 1997-05-29 | 1997-05-29 | Venereal disease preventing medicine containing interferon |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97109122 CN1068226C (en) | 1997-05-29 | 1997-05-29 | Venereal disease preventing medicine containing interferon |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1200941A CN1200941A (en) | 1998-12-09 |
| CN1068226C true CN1068226C (en) | 2001-07-11 |
Family
ID=5170937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 97109122 Expired - Fee Related CN1068226C (en) | 1997-05-29 | 1997-05-29 | Venereal disease preventing medicine containing interferon |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1068226C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100344324C (en) * | 2004-01-16 | 2007-10-24 | 深圳市海王英特龙生物技术股份有限公司 | Cream of liposome of interferon |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1557479A (en) * | 2004-01-16 | 2004-12-29 | 深圳市海王英特龙生物技术股份有限公 | Interferon liposome emulsifiable paste |
-
1997
- 1997-05-29 CN CN 97109122 patent/CN1068226C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100344324C (en) * | 2004-01-16 | 2007-10-24 | 深圳市海王英特龙生物技术股份有限公司 | Cream of liposome of interferon |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1200941A (en) | 1998-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2357474T3 (en) | COMPOSITIONS AND ITS USE TO CATCH AND INACTIVATE PATHOGEN MICROBES AND SpermATOZIODS. | |
| US6328991B1 (en) | Composition and method for prevention of sexually transmitted diseases, including aids | |
| AU2001243431A1 (en) | Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa | |
| CN1218403A (en) | Methods and preparations for the prophylaxis and treatment of mucocutaneous various infections (especially sexually transmitted diseases including human immunodeficiency virus), inflammation, neoplasm or other types of diseases | |
| WO2008148018A2 (en) | Rapidly dispersible vaginal tablet that provides a bioadhesive gel | |
| CN1872026A (en) | New medicinal preparation for vagina | |
| CN103157095B (en) | Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof | |
| CN1068226C (en) | Venereal disease preventing medicine containing interferon | |
| McGregor et al. | Contraception and sexually transmitted diseases: interactions and opportunities | |
| WO2008147049A1 (en) | A lubricating composition comprising agents which induce the mocosal immunity and a preparation method thereof | |
| US6949255B2 (en) | Inhibitory chemical formulation with preservative system | |
| KR101100713B1 (en) | Pharmaceutical compositions for the treatment of fungal overlapping infections and fungal relapses comprising ascorbic acid | |
| CN102048729B (en) | Preparation for treating vaginitis | |
| CN103520262B (en) | A kind of lipid soluble gynecological gel | |
| US20060122095A1 (en) | Mucus formulation for mucosal surfaces and uses thereof | |
| CN1062739C (en) | Medicine for preventing sexual disease | |
| AU783242B2 (en) | Methods and devices for preventing transmission of sexually transmitted diseases | |
| CN1156302C (en) | Ointment capable of quick sterilizing AIDS, veneral virus and spermatozoa and preparation process thereof | |
| CN1232302C (en) | Compound preparation of Azithromycin and Pidotimod | |
| CN1470250A (en) | External-use disinfecting medicinal preparation for women | |
| CN1135978C (en) | Ointment for moistening and relaxing sexual function | |
| CN1202357A (en) | Medicine for curing sexual disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |